(Q56786460)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

review article

1 reference

title

New developments in anti-HIV chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

number of pages

18

1 reference

Biochimica et Biophysica Acta

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

1587

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

258-275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Sulfated polysaccharides extracted from sea algae as potential antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

A general model for the surface glycoproteins of HIV and other retroviruses.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Highly sulfated forms of heparin sulfate are involved in japanese encephalitis virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Polyanions--a lost chance in the fight against HIV and other virus diseases?

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Poly(sodium 4-styrene sulfonate): an effective candidate topical antimicrobial for the prevention of sexually transmitted diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Involvement of chemokine receptors in breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

HIV-1 entry inhibitors in the side pocket

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

ADA, a potential anti-HIV drug

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Azodicarbonamide inhibits T-cell responses in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3'-azido-2',3'-dideoxythymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Activities of masked 2',3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Cyclosaligenyl-2',3'-didehydro-2',3'-dideoxythymidine monophosphate: efficient intracellular delivery of d4TMP

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

(-)-6-Chloro-2-[(1-furo[2, 3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Retroviral integrase inhibitors year 2000: update and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Thiazolothiazepine inhibitors of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350).

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibition of human immunodeficiency virus type-1 integrase by curcumin

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Recent developments in HIV protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

A Convergent, Scalable Synthesis of HIV Protease Inhibitor PNU-140690

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4439%2802%2900089-3

7 January 2021

10.1016/S0925-4439(02)00089-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12084468%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference